A number of growth factors have been implicated in the control of the proliferation of breast cancer cells and some have been reported to mediate the proliferative effects of oestradiol. MCF-7 cells were treated with growth factors in the presence and absence of oestradiol. Oestradiol increased the response of cells to the proliferative effects of epidermal growth factor (EGF), transforming growth factor alpha (TGF-M) and basic fibroblast growth factor (bFGF). Platelet derived growth factor (PDGF) and cathepsin D had no effect in the presence or absence of oestradiol while TGF-P slightly reduced the stimulation by oestradiol. In the absence of oestradiol, there was little effect of combinations of growth factors although the effects of bFGF and IGF-I were additive. In the presence of oestradiol, the effects of bFGF and TGF-a were additive whereas bFGF acted as an IGF-I antagonist. Overall, bFGF had the greatest effect on cell proliferation although this was less marked than the previously described effect of the IGFs and insulin. (Lippman et al., 1976; Johnson et al., 1989) . They therefore provide useful systems for studying the interactions between various growth factors and for understanding the mechanisms involved in the stimulation of proliferation by oestrogens and the interactions between growth factors and steroids.
The factors which control the proliferation of breast cancer cells are not well defined. Breast tumours express variable levels of receptors for steroids (McGuire et al., 1975; Osborne et al., 1980) and growth factors (Cullen et al., 1989) and it has been proposed that the ligands for these receptors act through a variety of autocrine and paracrine mechanisms. Studies in vivo and in cell culture systems have implicated a number of steroids and polypeptide growth factors (Lippman et al., 1988) but the relative contribution of each growth factor and the precise way in which each acts is not known.
Breast cancer cell lines provide tractable experimental systems for examining some aspects of the control of breast cancer cell proliferation. Furthermore some cell lines such as the MCF-7 cell line contain oestrogen receptors and their proliferation is regulated by oestrogens (Lippman et al., 1976; Johnson et al., 1989) . They therefore provide useful systems for studying the interactions between various growth factors and for understanding the mechanisms involved in the stimulation of proliferation by oestrogens and the interactions between growth factors and steroids.
Transforming growth factors (TGFs), insulin-like growth factors (IGFs), fibroblast growth factors (FGFs), platelet derived growth factor (PDGF) and epidermal growth factor (EGF) as well as other proteins such as cathepsin D have all been implicated in the control of breast cancer cell proliferation. Some of these growth factors, such as PDGF, are thought to be synthesised by tumour cells but to influence breast cancer cell proliferation indirectly by regulating the synthesis of other growth factors in stromal cells (Bronzert et al., 1987) . Other proteins, such as the transforming growth factors (Bates et al., 1988; Knabbe et al., 1987) and cathepsin D (Vignon et al., 1986) have been reported to be synthesised by tumour cells and may act as autocrine mitogens. Regulation of the synthesis of autocrine growth factors such as TGF-a (Bates et al., 1988) and TGF-,B (Knabbe et al., 1987) by oestrogens and antioestrogens has been reported and may contribute to mediating the effects of oestrogens on breast cancer cell proliferation.
The insulin-like growth factors are increasingly being implicated in the control of the proliferation of a wide variety of tumour cells (reviewed in Westley and May, 1991) and these proliferative effects are generally thought to be mediated through the type I IGF receptor. In some instances it has been proposed that tumour cells respond to exogenous IGFs, whereas in others such as small cell lung carcinoma, there is well documented evidence that IGF-I functions as an autocrine growth factor (Minuto et al., 1988) . In breast cancer, there is now a concensus that the cancer cells do not produce biologically significant amounts of IGF-I (Yee et al., 1991) although some appear to produce IGF-II (Osborne et al., 1989) . We have reported that oestrogens sensitise breast cancer cells to the proliferative effects of IGFs (Stewart et al., 1990) (Reid et al., 1986) .
Cell culture MCF-7 cells were maintained in Dulbecco's Modified Eagles medium supplemented with foetal calf serum (10%) and porcine insulin (1 ;ig ml-1).
Growth experiments were performed as described previously (Johnson et al., 1989) . Cells (10,000) were plated in 16-mm diameter wells in 0.5 ml and allowed to attach over 2 days. Prior to treatment, the cells were progressively withdrawn from the oestrogens present in the normal growth medium as described by Johnson et al. (1989) . This involved culturing the cells in phenol red-free modified Eagle's medium supplemented with charcoal-treated newborn calf serum (10%) and insulin (1 ,tg ml-1) for 4 days. The medium was changed twice daily for the first 3 days with a PBS wash at every change. The cells were then cultured for a further 6 or 9 days in this medium which was supplemented with REGULATION OF BREAST CANCER CELLS BY OESTROGEN AND GROWTH FACTORS 641 oestradiol and various combinations of growth factors. Culture medium was changed daily.
DNA assay DNA was measured using bisbenzimidazole (Hoechst 33258) as described previously (Johnson et al., 1989) . FGF binding FGF binding was measured essentially as described by Kan et al. (1988) . MCF-7 cells (20,000) were plated into 16 mm wells in normal growth medium. When the cells were 40% confluent, they were withdrawn from oestrogens present in normal growth medium as described for the growth experiments and then cells were treated with 10 nM oestradiol for 2 days or cultured for a further 2 days in withdrawal medium alone. Cell monolayers were washed with phosphatebuffered saline containing 1 mg ml-I BSA (PBS/BSA) and then incubated with varying concentrations of '25I-bFGF (1,400 Ci mmol-', Amersham, UK) in the presence and absence of a 100 fold molar excess of unlabelled bFGF in binding buffer (PBS/BSA supplemented with 2 tg ml1l heparin) for 2 h on ice. The cells were then washed four times with 0.5 ml of binding buffer and the bound '25I-bFGF was then extracted by incubation with 1% triton X-100 for 15min on ice. The '25I-bFGF in the extraction buffer was measured in a gamma counter. Total and non-specific binding was measured in triplicate.
cDNA hybridisation Plasmids pDC1 15 and pCD1 16 containing cDNA corresponding to the extracellular domains of the flg and bek FGF receptors respectively (Dionne et al., 1990) were labelled with 32P-dCTP by random priming. MCF-7 cells were withdrawn from oestrogens, and then treated for two days with oestradiol (10 nM) for 2 days as described above. Prior to treatment, cells were cultured in phenol red-free medium containing charcoal-stripped serum. This medium has been shown previously to contain extremely low levels of oestrogen (May & Westley, 1988) . After 5 days of culture in this medium, cells stop proliferating thus permitting small effects of added growth factors to be detected.
Under these culture conditions, oestradiol treatment routinely resulted in a two-four fold increase in cell numbers over 9 days. Addition of TGF-a or EGF alone ( 
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presence of oestradiol, TGF-x increased cell proliferation 3 fold at concentrations of 10 gml-l and above but only 1.2 fold in the absence of oestradiol. For EGF half-maximal stimulation was observed at a somewhat lower concentration (1 ng ml-') but the maximal stimulation was similar to that observed for TGF-o. Pro-cathepsin D has been reported to be mitogenic for MGF-7 cells (Vignon et al., 1986) . To test the mitogenic activity of mature cathepsin D, MCF-7 cells were treated with mature human cathepsin D purified from spleen. Figure  3a shows that there was no effect of cathepsin D (5 ng ml-1) on proliferation in the presence or absence of oestradiol and this was true for all concentrations tested (1, 5 and 50 ng ml-'). PDGF is a motogen which acts as a competence factor for fibroblasts. The mitogenic activity of PDGF was measured on MCF-7 cells in the presence and absence of oestrogen. Figure 3b shows that PDGF had no effect on cell proliferation and did not modulate the proliferative effect of oestradiol at a concentration 1O ng ml-. PDGF was then tested at a higher concentration (100 ng ml-') but again had no effect on the proliferation of withdrawn or oestrogentreated MCF-7 cells. Figure 4a and b show similar experiments with TGF-P and bFGF respectively. TGF-P alone had no effect on cell proliferation but marginally inhibited the stimulation of cell proliferation induced by oestradiol. bFGF alone marginally increased cell proliferation (1.4 fold) but treatment of MCF-7 cells with bFGF and oestradiol resulted in a significantly greater stimulation (8.8 fold) of growth than obtained with oestradiol alone (5 fold).
Effects of combinations ofgrowth factors on MCF-7 cell proliferation in the presence and absence of oestradiol Few studies have examined the effects of combinations of growth factors on the proliferation of breast cancer cells and none have studied the modulation of the effects of combinations of growth factors by oestradiol. The growth inhibitory effect of TGF-0 on breast cancer cell proliferation (Knabbe et al., 1987) has provoked much interest. We have previously reported that insulin markedly stimulates the proliferation of breast cancer cells in the presence of oestradiol and we therefore examined whether TGF-P could inhibit the large stimulation of proliferation when MCF-7 cells are treated with insulin and oestradiol. Figure 5 shows the dramatic synergism between oestradiol and insulin. In this experiment, the stimulation by oestradiol and insulin together was five fold that observed for oestradiol alone. As in the experiment shown in Figure 4 , TGF-P marginally decreased oestrogen-induced proliferation but did not reduce the much higher level of proliferation of cells treated with insulin and oestradiol together.
Of the growth factors which stimulated the proliferation of MCF-7 cells, TGF-a, EGF and bFGF (Figures 1-4) had the most pronounced effects. TGF-o and EGF had similar effects on the proliferation of MCF-7 cells, are both thought to act through the EGF receptor and are therefore unlikely to have an additive effect. However, as TGF-o and bFGF interact with different receptors, the effects of TGF-x together with bFGF were measured in the absence and presence of oestradiol. In the absence of oestradiol, both growth factors had little effect either alone or in combination (Figure 6a ). In the presence of oestradiol, however, treatment of cells with TGFa and bFGF resulted in a greater stimulation of proliferation (8.5 fold) than with either growth factor alone (Figure 6b ). This experiment emphasised the dependence of the activity of these two growth factors on the presence of oestradiol and showed that they could also have additive effects in the presence of oestradiol.
Finally, the interaction between IGF-I and FGF was measured in the absence and presence of oestradiol to determine if bFGF could increase the proliferation stimulated by IGF-I. In the absence of oestradiol, neither IGF-I nor bFGF significantly increased cell proliferation but IGF-I and bFGF increased cell numbers two-fold after 9 days of treatment (Figure 7a ). In the presence of oestradiol, however, bFGF Time of treatment (days) Figure 4 Effect of TGF-P a, and bFGF b, on MCF-7 cell proliferation in the presence and absence of oestradiol. MCF-7 cells were plated and withdrawn as described in the Materials and methods. In a, cells were cultured in withdrawal medium alone (0, C), withdrawal medium supplemented with TGF-P (10 ng ml-', 0, TGF P), oestradiol alone (10 nm, 0, E2). In b, cells were cultured in withdrawal medium alone (0, C), withdrawal medium supplemented with bFGF (10 ng ml-', 0, bFGF), oestradiol alone (10 nm, 0, E2) or oestradiol together with bFGF (U, bFGF + E2). Cell numbers were measured as described in the legend to inhibited the effects of IGF-I so that the number of cells after 9 days of treatment was similar to that following treatment with bFGF in the presence of oestradiol (Figure 7b) . The concentrations of bFGF which were synergistic with oestradiol and which inhibited the effect of IGF-I in the presence of oestradiol were defined by culturing MCF-7 cells in the presence of various concentrations of bFGF with oestradiol alone or IGF-I together with oestradiol ( Figure 8 ). Both effects of bFGF were dose dependent and were maximal at lOOpgml1'. However, significant antagonist effects were observed at 1 and 10 pg ml1' whereas no agonist effects were observed at this concentration. Half maximal stimulation in the presence of oestradiol alone was observed at 30 pg while half maximal inhibition in the presence of oestradiol and IGF-I occurred at 7 pg bFGF.
Characterisation of bFGF binding to MCF-7 cells bFGF had the clearest synergistic effect of the growth factors used in this study. We have previously reported that oestradiol increases expression of the type I IGF receptor on MCF-7 cells (Stewart et al., 1990) 
Discussion
Although there have been extensive studies on the effects of growth factors on the proliferation of breast cancer cells as well as on the production of growth factors by breast cancer cells, there have been relatively few studies on the interaction between steroids and growth factors. Given that oestrogens are important in tumour development in vivo and that oestrogens may mediate their effects through growth factor pathways, this is an area of some importance. The analysis of the effects of oestrogens on breast cancer cells has been facilitated by the development of oestrogenfree culture conditions and the withdrawal of cells from oestrogens present in normal culture media prior to treatment. This involves the use of phenol-red free medium supplemented with stripped serum and a withdrawal period which involves frequent changes of medium to remove the influences of steroids present in normal growth medium. These culture conditions have been used to identify oestrogen regulated mRNAs in breast cancer cells (May & Westley, 1988) and to study the effects of antioestrogens on the expression of oestrogen regulated genes (Johnson et al., 1989) .
We have previously reported that oestrogens sensitise three oestrogen responsive breast cancer cell lines to the proliferative effects of IGFs (Stewart et al., 1990) . In the present study we have examined the ability of oestrogen to modulate (Karey & Sirbasku, 1988; Bronzert et al., 1987) and is consistent with the inability to detect receptors for PDGF on MCF-7 cells. The lack of effect of cathepsin D in the presence and absence of oestradiol is in agreement with the data of Karey and Sirbasku (1988) . A stimulation of growth by purified procathepsin D has, however, been reported for MCF-7 cells (Vignon et al., 1986) . EGF and TGF-(x alone both stimulated cell proliferation considerably less than did oestradiol alone. This suggests that addition of TGF-a to the culture medium cannot substitute for oestradiol and this argues that the induction of TGF-a cannot be responsible for mediating all the effects of oestradiol on cell proliferation as was proposed by Bates et al. (1988) . Furthermore, proliferation in the presence of TGF-xc or EGF and oestradiol was actually greater than in the presence of oestradiol alone and this is not consistent with either growth factor acting as an oestrogen-induced autocrine growth factor. Experiments with transfected cell lines which express high levels of TGF-x constitutively but which retain oestrogen responsiveness , and the identification of an oestrogen responsive cell line which does not express epidermal growth factor receptor which mediates the effects of TGF-x (Leung et al., 1987) , have also suggested that TGF-a plays a relatively minor role as an oestrogen induced autocrine mitogen and are consistent with our data. Although the cooperative effects of growth factors on the proliferation of cells such as fibroblasts is well documented and has given rise to the concept of competence and progression factors, the interaction of growth factors in the control of the proliferation of breast cancer cells is poorly understood.
bFGF was first reported to act as a mitogen for breast cancer cells by Karey and Sirbasku (1988) although it had previously been shown to stimulate the growth of rat mammary myoepithelial and stromal cell lines (Rudland et al., 1977; Smith et al., 1984) . In this study, bFGF alone increased cell numbers to a limited extent in the absence of oestradiol but in contrast to the other growth factors tested, bFGF acted synergistically with oestradiol. This effect is similar to, though not as dramatic as, the synergism observed previously between oestradiol and the IGFs (Stewart et al., 1990) . We have suggested that oestrogens sensitise breast cancer cells to the mitogenic effects of IGFs and have shown that oestrogen stimulated cells express more type I IGF receptor on the cell surface which may account for the increased response to IGFs (Stewart et al., 1990) . The situation with FGF receptors appears to be different. FGF binding was detected on MCF-7 cells but was not increased by oestrogens. The synergism between oestrogens and bFGF could therefore result from an effect of oestrogen on the post-receptor signal transduction pathway or even an effect of bFGF on components of the oestrogen receptor pathway.
In this study, the interaction of bFGF with TGF-o and IGF-I were studied as these three growth factors had the most significant effects on the proliferation of MCF-7 breast cancer cells. Interestingly, the effects observed depended on the combination of growth factors and the presence of oestradiol. In the absence of oestradiol, TGF-a and bFGF had little effect either singly or in combination whereas in the presence of oestradiol the much larger effects of these two growth factors were additive and together gave rise to a large stimulation in cell numbers. This contrasted with the results obtained when IGF-I and bFGF were combined. In the absence of oestradiol, the effects of IGF-I and bFGF were additive whereas in the presence of oestradiol, bFGF appeared to act as an IGF-I antagonist. There are few reports of bFGF inhibiting cell growth although Kan et al. (1988) have reported that bFGF inhibits the growth of a hepatoma cell line and this has been linked to the expression of a class of low affinity FGF receptors on the cell surface. In MCF-7 cells, a higher concentration of bFGF was required to stimulate proliferation in the presence of oestradiol alone than was required to inhibit the proliferation stimulated by oestradiol and IGF-I together. It is possible that in this case, the agonist and antagonist effects of bFGF may be mediated by two different receptors and that oestrogen and IGFs modulate the transmission of positive and negative signals from these different receptors.
The experiments described in this study have demonstrated that the response of cells to growth factors can be modulated by steroids and other growth factors. Clearly the situation in breast tumours is complex because of the presence of multiple cell types and because breast tumours from different individuals can express widely varying levels of a variety of growth factors and their receptors. However, experiments such as those described in this study using cultured breast cancer cells should help to identify the growth factors and signal transduction systems which exert the greatest influence on breast cancer cell proliferation and may ultimately help to identify novel therapeutic targets for breast cancer treatment.
